FILTER

Refine your search with the following facets to narrow down your results.

10 Current news of Helix BioPharma

Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b

09-Nov-2009 - Helix BioPharma Corp. announced that its Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW) has completed patient enrollment, with the required 120th patient randomized to enter the trial. The double-blind and placebo-controlled Phase II trial is underway ...

Germany interferon Sweden

Helix BioPharma Announces the Appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its Board of Directors

19-Aug-2009 - Helix BioPharma Corp. announced the appointment of Kazimierz Roszkowski-Sliz, M.D., Ph.D., to its board of directors. Professor Roszkowski-Sliz is replacing Professor Slawomir Majewski, who has stepped down from the board to assume the advisory role of European medical director for ...

lung cancer lung diseases

Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b

18-Mar-2009 - Helix BioPharma Corp. announced that it has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. The clinical study was designed, as mandated by regulatory ...

absorption cervical lesions dosing +4

Helix BioPharma awarded U.S. Patent for DOS47 adjunct chemotherapy applications

18-Sep-2007 - Helix BioPharma Corp. announced the issuance of its second DOS47 patent (U.S. Patent No. 7,264,800) from the United States Patent & Trademark Office, describing a method and composition for combining targeted DOS47 therapeutics with weakly basic chemotherapeutic drugs in adjunct treatment ...

adenocarcinoma chemotherapy lung cancer +1

Helix BioPharma awarded first U.S. Patent for DOS47

07-May-2007 - Helix BioPharma Corp. announced the issuance of a patent (U.S. Patent No. 7,211,250) from the United States Patent & Trademark Office relating to the method and composition in combining DOS47 with targeting agents in the treatment of cancer. Helix is currently developing its first DOS47-based ...

adenocarcinoma ammonia Enzyme +3

Helix BioPharma Corp. announces positive phase II clinical results with its Topical Interferon Alpha-2b

04-Apr-2007 - Helix announced positive results from its phase II clinical study of its Topical Interferon Alpha-2b in women with human papilloma virus (HPV) induced low-grade cervical lesions. The study showed a clinically efficacious response to treatment in nearly half of the treated patients. In addition, ...

cervical cancer cervical lesions dosing +4

Helix BioPharma Corp. signs L-DOS47 manufacturing agreement with BioVectra dcl

09-Jan-2007 - Helix BioPharma Corp. announced that it has signed an agreement with BioVectra, a division of Diagnostic Chemicals Limited ("BioVectra dcl"), to manufacture L-DOS47 bulk drug product for human clinical testing. During 2007, Helix intends to continue to work diligently on completing the remaining ...

adenocarcinoma ammonia animal experiments +3

Helix receives approval to conduct a clinical trial of Topical Interferon Alpha-2b in Sweden

15-Sep-2005 - Helix BioPharma announced that it has received approval from Sweden's drug regulatory authority, the Medical Products Agency (MPA), to conduct a Phase II clinical trial of Topical Interferon Alpha-2b in patients with ano-genital warts (condylomata acuminata), who are positive for infection with ...

clinical trials Germany interferon +2

Helix identifies lead product candidate from DOS47 cancer therapeutic program

09-May-2005 - Helix BioPharma announced the selection of its lead product candidate derived from its novel DOS47 cancer therapeutic program. L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific antibody, to form a potential new drug product for the treatment of adenocarcinoma of ...

adenocarcinoma ammonia clinical trials +2

Helix announces election of new board member

12-Jan-2005 - Helix BioPharma announced that, at its Annual General Meeting, Mr. Jack Kay, President and Chief Operating Officer of Apotex Inc., was elected to its board of directors. Mr. Kay has more than 40 years of experience in the pharmaceutical industry, primarily in senior executive positions. In ...